Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Shares Sold by Monaco Asset Management SAM

Monaco Asset Management SAM lessened its stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 17.1% in the 1st quarter, Holdings Channel reports. The firm owned 325,000 shares of the biopharmaceutical company’s stock after selling 67,262 shares during the period. Monaco Asset Management SAM’s holdings in Vanda Pharmaceuticals were worth $1,492,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of the stock. XTX Topco Ltd raised its position in shares of Vanda Pharmaceuticals by 378.3% during the 1st quarter. XTX Topco Ltd now owns 69,329 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 54,833 shares during the last quarter. GSA Capital Partners LLP raised its position in shares of Vanda Pharmaceuticals by 88.0% during the 1st quarter. GSA Capital Partners LLP now owns 260,215 shares of the biopharmaceutical company’s stock worth $1,194,000 after purchasing an additional 121,797 shares during the last quarter. Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Vanda Pharmaceuticals during the 1st quarter worth about $875,000. Bailard Inc. acquired a new position in shares of Vanda Pharmaceuticals during the 1st quarter worth about $103,000. Finally, Linden Thomas Advisory Services LLC acquired a new position in shares of Vanda Pharmaceuticals during the 1st quarter worth about $49,000. Institutional investors and hedge funds own 88.14% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on VNDA shares. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Vanda Pharmaceuticals in a research report on Wednesday, May 14th. Wall Street Zen upgraded shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, June 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a report on Wednesday, May 7th.

Vanda Pharmaceuticals Trading Down 0.4%

VNDA stock opened at $4.68 on Wednesday. The company has a market cap of $275.81 million, a price-to-earnings ratio of -6.24 and a beta of 0.68. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $6.04. The firm has a 50-day moving average of $4.63 and a two-hundred day moving average of $4.54.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The company had revenue of $50.04 million during the quarter, compared to the consensus estimate of $45.13 million. Vanda Pharmaceuticals had a negative net margin of 21.98% and a negative return on equity of 8.30%. As a group, equities analysts forecast that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Stephen Ray Mitchell sold 7,000 shares of the firm’s stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $4.59, for a total transaction of $32,130.00. Following the completion of the sale, the director owned 97,082 shares in the company, valued at $445,606.38. This trade represents a 6.73% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Mihael Hristos Polymeropoulos purchased 10,000 shares of the business’s stock in a transaction dated Wednesday, May 21st. The shares were purchased at an average price of $4.40 per share, with a total value of $44,000.00. Following the acquisition, the chief executive officer directly owned 2,325,731 shares in the company, valued at approximately $10,233,216.40. The trade was a 0.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. 8.90% of the stock is owned by company insiders.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.